MannKind says it may partner on Afrezza but will retain full rights

MannKind Corporation held an investor call on February 3, 2016 in which CEO Matt Pfeffer said that the company might co-promote Afrezza inhaled insulin with a partner or partners after Sanofi returns the rights, but that MannKind would retain full rights to the product and will market Afrezza itself after the transition, which is anticipated . . . Read more

Spiriva Respimat now available in the US for the treatment of asthma

Spiriva Respimat is now available in US pharmacies for the treatment of asthma, Boehringer Ingelheim has announced. The FDA approved Spiriva Respimat for the treatment of asthma in patients aged 12 and older in September 2015. The tiotropium bromide soft mist inhaler was approved by the FDA for the treatment of COPD in September 2014 . . . Read more

Discovery Labs appoints Craig Fraser as President and CEO, provides update on Aerosurf program

Discovery Laboratories, which recently released positive Phase 2a data for its Aerosurf aerosolized KL4 surfactant and advanced the product into Phase 2b, has announced the appointment of Craig Fraser as President and CEO. Fraser was most recently Chief Operating Officer of Aegerion Pharmaceuticals and previously held positions at Pfizer, Wyeth, and Johnson & Johnson. Previous . . . Read more